BridgeBio Pharma Long Term Debt

As of the most recent data (March 2026), BBIO shows a long-term debt of $14M. That compares with $4.9M in the prior-year period — up 189.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BBIO's long-term debt is now $14M (was $4.9M) — a 189.2% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether BridgeBio Pharma is outperforming or lagging.

Tracking BBIO's long-term debt over time shows whether BridgeBio Pharma is scaling, shrinking, or reshaping that part of the business. The current reading is $14M That compares with $4.9M in the prior-year period — up 189.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has BridgeBio Pharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $14M) with ownership activity and broader fundamentals.

BridgeBio Pharma's long-term debt is $14M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.